Venture Life Group (LON:VLG) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

Shares of Venture Life Group plc (LON:VLG) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 60.91 and traded as high as GBX 68. Venture Life Group shares last traded at GBX 66, with a volume of 763,578 shares trading hands.

Venture Life Group Stock Down 1.5%

The stock has a market capitalization of £80.41 million, a P/E ratio of 15.10, a P/E/G ratio of 5.67 and a beta of 0.23. The firm’s fifty day moving average is GBX 60.91 and its 200-day moving average is GBX 64.40. The company has a current ratio of 4.71, a quick ratio of 1.48 and a debt-to-equity ratio of 0.82.

Venture Life Group (LON:VLG) last announced its quarterly earnings results on Tuesday, March 31st. The company reported GBX (1.49) earnings per share (EPS) for the quarter. Venture Life Group had a net margin of 17.42% and a return on equity of 7.82%. The firm had revenue of GBX 3,517 million for the quarter. As a group, equities research analysts predict that Venture Life Group plc will post 6.1391542 earnings per share for the current year.

Insider Transactions at Venture Life Group

In other news, insider Paul McGreevy purchased 48,373 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of GBX 62 per share, with a total value of £29,991.26. Over the last ninety days, insiders have bought 80,207 shares of company stock worth $5,004,160. Company insiders own 7.27% of the company’s stock.

About Venture Life Group

Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.

Headquartered in the UK, the Group’s product portfolio includes Balance Activ in the area of women’s intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.